MARKET WIREYahoo! Finance Canada • 1d ago
Phunware, Inc. (PHUN) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Black Titan Corporation (BTTC) market action, institutional positioning, and fundamental catalysts.
Why BTTC Stock dropped -3.17% Today — RQD Quant Desk Flash
$0.31 -3.17% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.31
Black Titan Corporation (BTTC) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $4.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on BTTC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is BTTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Black Titan Corporation (NASDAQ: BTTC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.31 (-3.17% 1D, market cap $4.8M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BTTC ranks #522 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does BTTC compare to CELZ and CRIS in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BTTC carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CELZ (Creative Medical Technology Holdings Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $5.0M) and CRIS (Curis Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $4.0M). Among the 5-stock peer group, BTTC leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for BTTC?
▼
Per BTTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-07-31, CIK 0002034400), Black Titan Corporation generated $869.2K in revenue, -$163.2K in net income, and -$143.2K in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.31 (-0.76%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-9.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BTTC)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (38/100 Composite)
🔍 WHY BTTC SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+10/20 pts (26% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 38.6% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$0.44-15.9% Next Q
46
Q2 (-2Q)Grade D$0.37-5.4% Next Q
43
Q3 (-1Q)Grade D$0.35-11.4% Next Q
41
CurrentGrade D-$0.31-7.8% Hist 90D α
38
Trajectory: D (46) → D- (38)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a BTTC Turnaround Squeeze
While BTTC currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.44) and Max Pain ($0.33) forces dealer call-delta covering toward $10.55.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $BTTC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BTTC Beats Next Quarter EPS Consensus (Jan 28, 2027) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BTTC Stock dropped -3.17% Today — RQD Quant Desk Flash
Black Titan Corporation (BTTC) dropped -3.17% to $0.31, trading at 2% of its 52-week range ($0.32 – $10.05). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.32 – $10.05) with RSI-14 at 38 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.31 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 38.6% gross margin and $0 annual free cash flow.
Live BTTC Headlines & Catalysts
MARKET WIREYahoo! Finance Canada • 1d ago
Youxin Technology Ltd (YAAS) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Black Titan Corporation (BTTC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
Ahasolar Technologies Limited (AHASOLAR.BO) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Black Titan Corporation (BTTC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
AXIL Brands, Inc. (AXIL) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Black Titan Corporation (BTTC) market action, institutional positioning, and fundamental catalysts.
CATALYSThttps://www.dars.gov.et/ • 1d ago
Arena Group Holdings (AREN) Surges 19% to $1.12, Pressing Against $1.18 Resistance - Index Put Callhttps://www.dars.gov.et/ report covering Black Titan Corporation (BTTC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 189d ago
Aterian, Inc. Announces Definitive Agreement for the Sale of its Marquee Brand Portfolio for $18 Million Subject to AdjustmentsCompany Also Announces $7 Million Strategic Investment and Associated Leadership TransitionSUMMIT, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Aterian, Inc. (Nasdaq: ATER) (“Aterian” or the “Company”), a consumer products c
MARKET WIREYahoo Finance • 284d ago
Institutional Access via Public Equities: Black Titan's Strategic PivotNEW YORK, NY / ACCESS Newswire / January 23, 2026 / As the "DeFi-as-a-Service" (DaaS) narrative matures, public equity markets are witnessing a new phenomenon: the "Infrastructure Pivot." This week's primary focus is Bla
MARKET WIREYahoo Finance • 286d ago
Early & Accessible InvestingNEW YORK CITY, NEW YORK / ACCESS Newswire / January 20, 2026 / The very concept of an "investment" is being redefined. High barriers to entry are being dismantled by technology, creating a more democratized landscape. Th
MARKET WIREYahoo Finance • 286d ago
Digital-First Banking & PaymentsNEW YORK, NY / ACCESS Newswire / January 20, 2026 / A generation is coming of age with no memory of, or patience for, traditional banking. Their expectation is a financial world that lives on a mobile device - instant, i
MARKET WIREYahoo Finance • 290d ago
Black Titan Secures $200 Million from a U.S.-Based Institutional Investor to Scale Its DAT+ VisionNEW YORK, NY / ACCESS Newswire / January 16, 2026 / Black Titan Corporation (NASDAQ:BTTC) (the "Company" or "Black Titan") today announced that it has entered into a securities purchase agreement with a U.S.-based instit
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BTTC)
- ✓Walkthrough of BTTC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BTTC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -74.80%▼ DESCENDING CHANNEL
2026-11-03O $0.35H $0.35L $0.31C $0.31VOL 208.4K
RES: $0.84SUP: $0.16SMA50: $0.44SMA200: $1.02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BTTC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on BTTC today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BTTC. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BTTC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BTTC)
Health Care Rank #522 of 1015
⚔️ CELZ vs BTTC Full Matrix →
1. Head-to-Head Health Care Peer Comparison (BTTC vs. CELZ, CRIS, LIMN, PMCB)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Black Titan Corporation (BTTC) ranks #522 by composite RQD confidence (38/100, grade D-) and #947 by equity capitalization ($4.8M). Within this direct 5-issuer industry benchmark cohort, BTTC leads on earnings valuation at N/A trailing P/E, while PMCB leads on capital efficiency and profitability with -30.2% ROIC and — gross margin. BTTC currently leads its immediate peer cohort in composite quantitative strength at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BTTC
ACTIVE
Black Titan Corporation | D- | 38/100 | — | — | — | -3.17% | $4.8M | Benchmark Subject |
| CELZ Creative Medical Technology Holdings Inc. | E | 20/100 | — | 63.4% | -35.0% | -4.81% | $5.0M | /celz-vs-bttc → |
| CRIS Curis Inc. | E | 27/100 | — | — | -35.0% | +10.17% | $4.0M | /cris-vs-bttc → |
| LIMN Liminatus Pharma Inc. (Class A) | D- | 35/100 | — | — | -35.0% | -10.64% | $3.8M | /limn-vs-bttc → |
| PMCB PharmaCyte Biotech Inc. | E | 34/100 | — | — | -30.2% | +2.71% | $3.2M | /pmcb-vs-bttc → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)
SEC EDGAR 10-K • FILED 2025-07-31 • CIK 0002034400 ↗In its most recent audited fiscal period (FY2025, filed 2025-07-31), Black Titan Corporation (BTTC) reported GAAP revenue of $869.2K , GAAP net income of -$163.2K, operating cash flow of -$143.2K, and free cash flow of -$143.2K . On the balance sheet, BTTC closed FY2025 with $0 in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-07-31 | $869.2K | -$163.2K | -$143.2K | -$143.2K | — | — |
3. BTTC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BTTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Black Titan Corporation (NASDAQ: BTTC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.31 (-3.17% 1D, market cap $4.8M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BTTC ranks #522 in composite RQD confidence.
How does BTTC compare to CELZ and CRIS in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BTTC carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CELZ (Creative Medical Technology Holdings Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $5.0M) and CRIS (Curis Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $4.0M). Among the 5-stock peer group, BTTC leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BTTC?
Per BTTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-07-31, CIK 0002034400), Black Titan Corporation generated $869.2K in revenue, -$163.2K in net income, and -$143.2K in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BTTC trading relative to its 50-day, 200-day, and 52-week technical levels?
BTTC last traded at $0.31 (-3.17% on volume of 92,140 shares), positioning the stock -29.55% below its 50-day simple moving average ($0.44) and -69.61% below its 200-day simple moving average ($1.02). Across its 52-week range of $0.32 to $10.05, BTTC sits at the 0.0% percentile with a 14-day RSI of 38.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.35).
ROARABLE RATING BRIEF • RQD 38/100 (D-)
✓ SEC XBRL & RQD VERIFIED
BTTC — Black Titan Corporation: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-07-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Black Titan Corporation (BTTC) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.31 (-3.17% 1D, market capitalization $4.8M).
- Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of -2.73%.
- Whale 13F & Options Flow (6/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Black Titan Corporation trades on NASDAQ under the ticker BTTC. Industry.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-07-31), Black Titan Corporation (BTTC) reported $869.2K in annual revenue and -$163.2K in GAAP net income. Operating cash flow reached -$143.2K and free cash flow totaled -$143.2K, backed by $0 in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 38/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -2.73% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $0.32 – $10.05 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Sector correlation and second-order bottlenecks cannot be mapped from the provided materials. A prospective investor should note that the absence of mapped links means ripple effects from suppliers, customers, or peer companies cannot be assessed here.
- Key Question #1: Can BTTC sustain or expand its — operating margin and — ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $869.2K and free cash flow of -$143.2K, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is BTTC's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
BTTC Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Black Titan Corporation (BTTC) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Phunware, Inc. (PHUN) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Black Titan Corporation (BTTC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Youxin Technology Ltd (YAAS) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Black Titan Corporation (BTTC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Ahasolar Technologies Limited (AHASOLAR.BO) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Black Titan Corporation (BTTC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
AXIL Brands, Inc. (AXIL) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Black Titan Corporation (BTTC) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST https://www.dars.gov.et/ • 1d ago
Arena Group Holdings (AREN) Surges 19% to $1.12, Pressing Against $1.18 Resistance - Index Put Call https://www.dars.gov.et/ report covering Black Titan Corporation (BTTC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 189d ago
Aterian, Inc. Announces Definitive Agreement for the Sale of its Marquee Brand Portfolio for $18 Million Subject to Adjustments Company Also Announces $7 Million Strategic Investment and Associated Leadership TransitionSUMMIT, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Aterian, Inc. (Nasdaq: ATER) (“Aterian” or the “Company”), a consumer products c
🟡 MARKET WIRE Yahoo Finance • 284d ago
Institutional Access via Public Equities: Black Titan's Strategic Pivot NEW YORK, NY / ACCESS Newswire / January 23, 2026 / As the "DeFi-as-a-Service" (DaaS) narrative matures, public equity markets are witnessing a new phenomenon: the "Infrastructure Pivot." This week's primary focus is Bla
🟡 MARKET WIRE Yahoo Finance • 286d ago
Early & Accessible Investing NEW YORK CITY, NEW YORK / ACCESS Newswire / January 20, 2026 / The very concept of an "investment" is being redefined. High barriers to entry are being dismantled by technology, creating a more democratized landscape. Th
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
BTTC Bull vs. Bear Conversation Board — What's Your Call at $0.31?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BTTC 🐻 33% BEARISH CONVICTION
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH
🎯 Target: $0.41 (+28.1%)
📌 Pinned Debate The stock trades at $0.35 with a beta of 1.0 and a Piotroski-to-Altman mix that is not in distress territory, leaving room for a cash-f
The street is overcomplicating Black Titan Corporation (BTTC). The stock trades at $0.35 with a beta of 1.0 and a Piotroski-to-Altman mix that is not in distress territory, leaving room for a cash-flow turnaround to re-rate a deeply depressed price.. With an RQD score of 38/100 (D-) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $0.35.
SectorRotator 🐂 BULL
@SiliconVal_Bull Agree on the RQD 38/100 quality, though with 1.0 beta I'm scaling in with half-size at $0.32 and keeping dry powder in case we test $0.30.
SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH
🎯 Target: $0.25 (-21.9%)
Spot @ $0.32 The company reported zero revenue and a -$0.2M net loss in FY 2025 with ROIC at 0% and a Piotroski F-Score of 1/9, signaling weak funda
Sitting on the sidelines or leaning short BTTC above $0.32. The company reported zero revenue and a -$0.2M net loss in FY 2025 with ROIC at 0% and a Piotroski F-Score of 1/9, signaling weak fundamentals and no visible path to cash generation.. Until Fundamental Cash Engine (10/20) and FCF yield (-2.73%) inflect higher, upside is capped near $10.05.